相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
Angelica Loskog et al.
BRITISH JOURNAL OF CANCER (2016)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Katelyn T. Byrne et al.
JOURNAL OF IMMUNOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma
Kristen B. Long et al.
CANCER DISCOVERY (2016)
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
Katelyn T. Byrne et al.
CELL REPORTS (2016)
Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
Ann L. White et al.
CANCER CELL (2015)
SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities
Shyra J. Gardai et al.
CANCER RESEARCH (2015)
Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
David L. Bajor et al.
CANCER RESEARCH (2015)
Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
Peter Johnson et al.
CLINICAL CANCER RESEARCH (2015)
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
Gregory L. Beatty et al.
GASTROENTEROLOGY (2015)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07) (vol 33, pg 2523, 2015)
Mamot
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates
Elizabeth A. Thompson et al.
JOURNAL OF IMMUNOLOGY (2015)
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Alfred Zippelius et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
Jose Medina-Echeverz et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
Sara M. Mangsbo et al.
CLINICAL CANCER RESEARCH (2015)
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
Michelle Fanale et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell frequency and patient survival
Jonathan M. Weiss et al.
HUMAN IMMUNOLOGY (2014)
Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2014)
Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/αCD40 Therapy
Jonathan M. Weiss et al.
JOURNAL OF IMMUNOLOGY (2014)
Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
F. Chowdhury et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
Linda C. Sandin et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Lee P. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2014)
CD40L expression permits CD8+ T cells to execute immunologic helper functions
Marco Frentsch et al.
BLOOD (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
Myriam N. Bouchlaka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy
Julia K. Tietze et al.
BLOOD (2012)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo
Chengwen Liu et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
John C. Byrd et al.
LEUKEMIA & LYMPHOMA (2012)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
Bart Burington et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
Holly M. Horton et al.
BLOOD (2010)
AdCD40L Immunogene Therapy for Bladder Carcinoma-The First Phase I/IIa Trial
Per-Uno Malmstrom et al.
CLINICAL CANCER RESEARCH (2010)
A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (Mab), Chi Lob 7/4
P. W. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus
Taha Elmetwali et al.
MOLECULAR CANCER (2010)
Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity
Jennifer A. McWilliams et al.
VACCINE (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications (vol 10, pg 328, 2010)
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
E. Oflazoglu et al.
BRITISH JOURNAL OF CANCER (2009)
Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects
Hyun-Il Cho et al.
CANCER RESEARCH (2009)
BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells
Saritha Kusam et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
Jonathan M. Weiss et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines
Cory L. Ahonen et al.
BLOOD (2008)
In vivo Expansion, Persistence, and Function of Peptide Vaccine-Induced CD8 T Cells Occur Independently of CD4 T Cells
Deepak Assudani et al.
CANCER RESEARCH (2008)
Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis
Cornelia Hoemig-Hoelzel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo
Phillip J. Sanchez et al.
JOURNAL OF IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages
Hillary D. Lum et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
CL Law et al.
CANCER RESEARCH (2005)
Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells
TNJ Bullock et al.
JOURNAL OF IMMUNOLOGY (2005)
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN
CL Ahonen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2:: Coordination of dendritic and CD8+ cell responses
WJ Murphy et al.
JOURNAL OF IMMUNOLOGY (2003)
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation:: induction of bax
JL Szocinski et al.
BLOOD (2002)
Phase I study of recombinant human CD40 ligand in cancer patients
RH Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
